In summary, these data suggest that integration of src inhibition with gemcitabine therapy may present a useful treatment regimen to overcome gemcitabine resistance and to inhibit tumor growth, metastasis and recurrence of triple-negative breast cancer cells. Here, SRC is linked to neoplasm.